Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.
No takes yet. Share an insight, caveat, or question.
Sipp et al. (2017) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: